Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

Delayed Quote. Delayed  - 08/29 10:00:00 pm
71.56 USD   +1.07%
08/29 ALNYLAM PHARMAC : Research Reports Initiation on Biotech Stocks -- H..
08/08 ALNYLAM PHARMAC : Completes Enrollment in ENDEAVOUR Phase 3 Study wi..
08/05 JACOBS ENGINEER : Nabs Engineering Services Contract for New Alnylam..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/23/2016 08/24/2016 08/25/2016 08/26/2016 08/29/2016 Date
75.79(c) 70.83(c) 69.35(c) 70.8(c) 71.56(c) Last
307 428 808 598 682 292 414 638 401 623 Volume
-0.51% -6.54% -2.09% +2.09% +1.07% Change
More quotes
Financials ($)
Sales 2016 39,2 M
EBIT 2016 -416 M
Net income 2016 -414 M
Finance 2016 645 M
Yield 2016 -
Sales 2017 60,0 M
EBIT 2017 -457 M
Net income 2017 -457 M
Finance 2017 573 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 138x
EV / Sales2017 91,7x
Capitalization 6 069 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.The... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
08/29 ALNYLAM PHARMACEUTICALS : Research Reports Initiation on Biotech Stocks -- Hemis..
08/25 ALNYLAM PHARMACEUTICALS : Patent Issued for Stable Non-Aggregating Nucleic Acid ..
08/18 ALNYLAM PHARMACEUTICALS : Completes Enrollment in ENDEAVOUR Phase 3 Study with R..
08/11 JACOBS ENGINEERING : Wins Contract for New Alnylam Biopharmaceutical Manufacturi..
08/08 ALNYLAM PHARMACEUTICALS : Completes Enrollment in ENDEAVOUR Phase 3 Study with R..
08/05 JACOBS ENGINEERING : Nabs Engineering Services Contract for New Alnylam Pharma F..
08/04 ALNYLAM PHARMACEUTICALS : reports 2Q loss
08/04 ALNYLAM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
08/04 ALNYLAM PHARMACEUTICALS : Researchers Submit Patent Application, "Methods and Co..
08/04 ALNYLAM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, F..
More news
Sector news : Biotechnology & Medical Research - NEC
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
08/05 Alnylam Pharmaceuticals, Inc. 2016 Q2 - Results - Earnings Call Slides
08/05 Alnylam Pharmaceuticals (ALNY) John M. Maraganore on Q2 2016 Results - Earnin..
08/04 Alnylam Pharmaceuticals beats by $0.19, beats on revenue
08/03 Notable earnings after Thursday?s close
07/29 Roche Quietly Takes Hemophilia Lead
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEU...
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 119 $
Spread / Average Target 67%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President & Chief Operating Officer
Michael W. Bonney Chairman
David-Alexandre Gros Chief Financial Officer
Akshay K. Vaishnaw Chief Medical Officer, EVP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICAL..-24.79%6 069
INCYTE CORPORATION-25.27%15 236
CELLTRION, INC.--.--%11 367
LONZA GROUP AG14.78%10 130
QUINTILES TRANSNATIONA..10.24%8 968
ALKERMES PLC-43.94%6 744
More Results